Participants 266 342 3
patients with large or locally advanced HER2-positive (HER2+) breast cancers
Participants 793 964 7
27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab, nab-paclitaxel and carboplatin combination therapy (BrUOG BR-211B (NCT00617942
